---
figid: PMC8005112__ijms-22-03228-g002
figlink: pmc/articles/PMC8005112/figure/ijms-22-03228-f002/
number: F2
caption: Potential mechanisms of synergy between small molecules and immune checkpoint
  inhibition in melanoma. Colored dots represent small molecule drugs. Intracellular
  ablation of Braf proto-oncogene/mitogen-activated protein kinase kinase (BRAF/MEK)
  in the mitogen activated protein kinase (MAPK) pathway (1), of oncogenic drivers
  such as those involved in the phosphoinositide-3-kinase/protein kinase B (PI3K/AKT)
  pathway or of other tyrosine kinases (2) induce apoptosis, resulting in increased
  presentation of neoantigens at the cell surface to primed and activated T-cells
  in the tumor microenvironment (TME). Extrinsic to the tumor cell, anti-angiogenic
  drugs (3) may impair nutrient delivery to tumor cells, resulting in tumor cell death
  and immune clearance. In the immune axis, immunomodulator drugs (4) may impair immunosuppressive
  cell types such as cancer associated fibroblasts (CAF), tumor associated macrophages
  (TAM), and myeloid derived suppressor cells (MDSC), including the cytokines they
  secrete which hinder cytotoxic T-cell function. Epigenetic modulator drugs may have
  bi-fold effects (5), exposing epigenetically silenced pathways (methylated, Me,
  or acetylated, Ac) within tumor cells, or alternatively activating pathways within
  immune effector cells including but not limited to immune checkpoints. APC (antigen
  presenting cell); MHC(major histocompatibility complex); RAS-GTP (Ras proto-oncogene
  guanosine triphosphate); ERK (extracellular signal-regulated kinases); PDK1 (phosphoinositide
  dependent kinase 1); TCR (T-cell receptor); PD-1 (programmed cell death protein-1);
  PD-L1 (programmed death-ligand 1); CTLA-4 (cytotoxic T-lymphocyte antigen 4).
pmcid: PMC8005112
papertitle: 'Thinking Small: Small Molecules as Potential Synergistic Adjuncts to
  Checkpoint Inhibition in Melanoma.'
reftext: Alexander C. Chacon, et al. Int J Mol Sci. 2021 Mar;22(6):3228.
pmc_ranked_result_index: '118392'
pathway_score: 0.9662142
filename: ijms-22-03228-g002.jpg
figtitle: Mechanisms of synergy between small molecules and immune checkpoint inhibition
  in melanoma
year: '2021'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8005112__ijms-22-03228-g002.html
  '@type': Dataset
  description: Potential mechanisms of synergy between small molecules and immune
    checkpoint inhibition in melanoma. Colored dots represent small molecule drugs.
    Intracellular ablation of Braf proto-oncogene/mitogen-activated protein kinase
    kinase (BRAF/MEK) in the mitogen activated protein kinase (MAPK) pathway (1),
    of oncogenic drivers such as those involved in the phosphoinositide-3-kinase/protein
    kinase B (PI3K/AKT) pathway or of other tyrosine kinases (2) induce apoptosis,
    resulting in increased presentation of neoantigens at the cell surface to primed
    and activated T-cells in the tumor microenvironment (TME). Extrinsic to the tumor
    cell, anti-angiogenic drugs (3) may impair nutrient delivery to tumor cells, resulting
    in tumor cell death and immune clearance. In the immune axis, immunomodulator
    drugs (4) may impair immunosuppressive cell types such as cancer associated fibroblasts
    (CAF), tumor associated macrophages (TAM), and myeloid derived suppressor cells
    (MDSC), including the cytokines they secrete which hinder cytotoxic T-cell function.
    Epigenetic modulator drugs may have bi-fold effects (5), exposing epigenetically
    silenced pathways (methylated, Me, or acetylated, Ac) within tumor cells, or alternatively
    activating pathways within immune effector cells including but not limited to
    immune checkpoints. APC (antigen presenting cell); MHC(major histocompatibility
    complex); RAS-GTP (Ras proto-oncogene guanosine triphosphate); ERK (extracellular
    signal-regulated kinases); PDK1 (phosphoinositide dependent kinase 1); TCR (T-cell
    receptor); PD-1 (programmed cell death protein-1); PD-L1 (programmed death-ligand
    1); CTLA-4 (cytotoxic T-lymphocyte antigen 4).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAP2K1
  - MAP2K2
  - BRAF
  - SMN1
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - CD274
  - PDK1
  - PDCD1
  - ARAF
  - RAF1
  - TRA
  - TRB
  - TRD
  - TRG
  - AKT2
  - AKT3
  - AKT1
  - MAPK3
  - MAPK1
  - ADCY2
  - ADCY3
  - ADCY5
  - ADCY6
  - ADCY8
  - ADCY9
  - ADCY10
  - ADCY4
  - ADCY1
  - ADCY7
  - CTLA4
  - APC
  - tyrosine
  - RAS-GTP
  - TCR
  - Ac
  - CAF
  - TAM
  - Melanoma
genes:
- word: 1BRAF/MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: 1BRAF/MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: BRAF/MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: BRAF/MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: BRAF/MEK
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Small
  symbol: SMA2
  source: hgnc_alias_symbol
  hgnc_symbol: SMN1
  entrez: '6606'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: PDK1
  symbol: PDK1
  source: hgnc_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY2
  entrez: '108'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY3
  entrez: '109'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY5
  entrez: '111'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY6
  entrez: '112'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY8
  entrez: '114'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY9
  entrez: '115'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY10
  entrez: '55811'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY4
  entrez: '196883'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY1
  entrez: '107'
- word: Ac
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY7
  entrez: '113'
- word: CTLA-4
  symbol: CTLA4
  source: hgnc_symbol
  hgnc_symbol: CTLA4
  entrez: '1493'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: APC
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
chemicals:
- word: tyrosine
  source: ''
  identifier: ''
- word: RAS-GTP
  source: MESH
  identifier: D006160
- word: TCR
  source: MESH
  identifier: D017260
- word: Ac
  source: MESH
  identifier: D000186
- word: CAF
  source: MESH
  identifier: C035000
- word: TAM
  source: MESH
  identifier: C419191
diseases:
- word: Melanoma
  source: MESH
  identifier: D008545
figid_alias: PMC8005112__F2
redirect_from: /figures/PMC8005112__F2
figtype: Figure
---
